Novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy

L Du, J Wang, Y Chen, X Li, L Wang, Y Li, X Jin… - Cell Biology and …, 2020 - Springer
Inflammation reaction mediated by NLRP3 inflammasome and Nrf2-related oxidative stress
are vital participants in the development of diabetic nephropathy (DN) and closely …

The selective NLRP3-inflammasome inhibitor CY-09 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3-inflammasome activation

M Yang, L Zhao - Current medicinal chemistry, 2023 - ingentaconnect.com
Background: Diabetic nephropathy (DN) is one of the most serious complications of diabetes
mellitus and the main cause of the end-stage renal disease (ESRD). Activation of the NLRP3 …

A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation

CX Zhang, XW Zhu, LL Li, TK Ma, M Shi… - … syndrome and obesity …, 2019 - Taylor & Francis
Background Diabetic nephropathy (DN) is a lethal diabetic microvascular complication
characterized by chronic low-grade inflammation. The NOD-like receptor pyrin domain …

WJ‐39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling

X Zhou, Z Liu, K Ying, H Wang, P Liu… - Oxidative Medicine …, 2020 - Wiley Online Library
Diabetic nephropathy (DN) is a chronic diabetic microvascular complication. Hyperactivity of
the polyol pathway is involved in the pathogenesis of DN. Aldose reductase (AR), the rate …

[HTML][HTML] Naringin ameliorates the high glucose-induced rat mesangial cell inflammatory reaction by modulating the NLRP3 Inflammasome

F Chen, G Wei, J Xu, X Ma, Q Wang - BMC Complementary and …, 2018 - Springer
Abstract Background The Nucleotide binding and oligomerization domain-like
receptorfamily pyrin domain-containing 3 (NLRP3)-inflammasome plays an important role in …

[HTML][HTML] Natural products in attenuating renal inflammation via inhibiting the NLRP3 inflammasome in diabetic kidney disease

Y Wang, Z Sui, M Wang, P Liu - Frontiers in Immunology, 2023 - frontiersin.org
Diabetic kidney disease (DKD) is a prevalent and severe complications of diabetes and
serves as the primary cause of end-stage kidney disease (ESKD) globally. Increasing …

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease

JA Østergaard, JC Jha, A Sharma, A Dai… - Clinical …, 2022 - portlandpress.com
Activation of nucleotide-binding oligomerization domain-like receptor pyrin domain
containing 3 (NLRP3) inflammasome has been reported in diabetic complications including …

[HTML][HTML] Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy

K Shahzad, F Bock, MM Al-Dabet, I Gadi, S Nazir… - Scientific reports, 2016 - nature.com
While a plethora of studies support a therapeutic benefit of Nrf2 activation and ROS
inhibition in diabetic nephropathy (dNP), the Nrf2 activator bardoxolone failed in clinical …

Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy

M Wu, Z Yang, C Zhang, Y Shi, W Han, S Song, L Mu… - Metabolism, 2021 - Elsevier
Background Nucleotide leukin-rich polypeptide 3 (NLRP3) inflammasome is documented as
a potent target for treating metabolic diseases and inflammatory disorders. Our recent work …

[HTML][HTML] TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy

J Shen, Z Dai, Y Li, H Zhu, L Zhao - Diabetology & metabolic syndrome, 2022 - Springer
Abstract Background Toll-like receptors (TLRs) are critical sensors for the conservation of
bacterial molecules and play a key role in host defense against pathogens. The effect of …